Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China
· Delayed Price · Currency is CNY 6.17
+0.26 (4.40%)
At close: Mar 10, 2026
SHA:688373 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | - | 386.26 | 166.31 | 151.09 | 145.52 | Upgrade
|
| Trading Asset Securities | - | 207.36 | 786.98 | 1,119 | 326.36 | Upgrade
|
| Cash & Short-Term Investments | 483.71 | 593.62 | 953.3 | 1,270 | 471.88 | Upgrade
|
| Cash Growth | -18.52% | -37.73% | -24.95% | 169.17% | -25.92% | Upgrade
|
| Accounts Receivable | - | 31.88 | 21.98 | 11.1 | 1.42 | Upgrade
|
| Other Receivables | - | 21.02 | 0.19 | 0.34 | 0 | Upgrade
|
| Receivables | - | 52.9 | 22.17 | 11.44 | 1.42 | Upgrade
|
| Inventory | - | 52.94 | 37.52 | 21.89 | 11.01 | Upgrade
|
| Other Current Assets | - | 49.21 | 41.27 | 67.01 | 25.29 | Upgrade
|
| Total Current Assets | - | 748.66 | 1,054 | 1,371 | 509.59 | Upgrade
|
| Property, Plant & Equipment | - | 75.8 | 86.21 | 97.46 | 122.8 | Upgrade
|
| Other Intangible Assets | - | 1.68 | 1.93 | 2.19 | 0.84 | Upgrade
|
| Long-Term Deferred Charges | - | 19.1 | 21.75 | 22.68 | 1.83 | Upgrade
|
| Other Long-Term Assets | - | 3.89 | 4.42 | 4.54 | 13.48 | Upgrade
|
| Total Assets | - | 849.13 | 1,169 | 1,497 | 648.54 | Upgrade
|
| Accounts Payable | - | 26.21 | 11.13 | 10.85 | 1.91 | Upgrade
|
| Accrued Expenses | - | 78.63 | 94.51 | 37.41 | 29.45 | Upgrade
|
| Short-Term Debt | - | 5 | - | 48.75 | 50.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | 89.23 | 14.15 | 10.1 | - | Upgrade
|
| Current Portion of Leases | - | 11.51 | 10.38 | 6.47 | 11.04 | Upgrade
|
| Current Income Taxes Payable | - | - | 4.41 | - | - | Upgrade
|
| Current Unearned Revenue | - | - | 0.13 | - | - | Upgrade
|
| Other Current Liabilities | - | 1.71 | 1.93 | 1.52 | 1.71 | Upgrade
|
| Total Current Liabilities | - | 212.3 | 136.65 | 115.11 | 94.19 | Upgrade
|
| Long-Term Debt | - | 122.94 | 114.96 | 70 | - | Upgrade
|
| Long-Term Leases | - | 73.18 | 81.7 | 94.89 | 99.87 | Upgrade
|
| Long-Term Unearned Revenue | - | 1.75 | 1.25 | 3.1 | 16.1 | Upgrade
|
| Total Liabilities | - | 410.16 | 334.56 | 283.1 | 210.17 | Upgrade
|
| Common Stock | - | 655.61 | 655.21 | 655.21 | 525.21 | Upgrade
|
| Additional Paid-In Capital | - | 1,571 | 1,532 | 1,495 | 636.77 | Upgrade
|
| Retained Earnings | - | -1,805 | -1,364 | -942.85 | -722.55 | Upgrade
|
| Comprehensive Income & Other | - | 17.08 | 10.91 | 7.19 | -1.06 | Upgrade
|
| Shareholders' Equity | 257.55 | 438.96 | 834 | 1,214 | 438.37 | Upgrade
|
| Total Liabilities & Equity | - | 849.13 | 1,169 | 1,497 | 648.54 | Upgrade
|
| Total Debt | 364.82 | 301.86 | 221.19 | 230.21 | 160.99 | Upgrade
|
| Net Cash (Debt) | 118.89 | 291.76 | 732.11 | 1,040 | 310.88 | Upgrade
|
| Net Cash Growth | -59.25% | -60.15% | -29.60% | 234.52% | -50.69% | Upgrade
|
| Net Cash Per Share | 0.18 | 0.45 | 1.12 | 1.79 | 0.59 | Upgrade
|
| Filing Date Shares Outstanding | 676.66 | 655.61 | 655.21 | 655.21 | 525.21 | Upgrade
|
| Total Common Shares Outstanding | 655.61 | 655.61 | 655.21 | 655.21 | 525.21 | Upgrade
|
| Working Capital | - | 536.37 | 917.61 | 1,255 | 415.39 | Upgrade
|
| Book Value Per Share | 0.39 | 0.67 | 1.27 | 1.85 | 0.83 | Upgrade
|
| Tangible Book Value | 256.46 | 437.28 | 832.07 | 1,212 | 437.53 | Upgrade
|
| Tangible Book Value Per Share | 0.39 | 0.67 | 1.27 | 1.85 | 0.83 | Upgrade
|
| Machinery | - | 14.41 | 14.18 | 11.75 | 6.01 | Upgrade
|
| Construction In Progress | - | - | - | - | 15.65 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.